Dr. Kriteman offers advice to urologists looking to utilize the HYDROS robotic system
“If you haven't used HYDROS before, or if you're concerned about doing bigger glands or tackling more difficult cases, I think we've shown in our first 35-40,000 cases that Aquablation, the therapy, is a valid therapy,” says Lewis S. Kriteman, MD, FACS.
In August 2024, the FDA granted 510(k) clearance to the HYDROS robotic system, an AI-powered platform designed to enhance the delivery of Aquablation therapy for patients with benign prostatic hyperplasia (BPH). In this video, Lewis S. Kriteman, MD, FACS, gives advice to urologists who are looking to implement the technology into their practice. Kriteman is a partner and urologist at Georgia Urology in Atlanta.
Video Transcript:
I would say, give this technology a chance. If you haven't used HYDROS before, or if you're concerned about doing bigger glands or tackling more difficult cases, I think we've shown in our first 35-40,000 cases that Aquablation, the therapy, is a valid therapy. It can work on prostates of all shapes and all sizes. And urologists who aren't necessarily newer or younger who are willing to look at newer technologies should look at this, because it is very, very easy to get up to speed. It will add something to your practice that you don't currently have, and that's the Swiss Army knife of BPH treatments that allows you to take care of small, medium, large glands, glands that have been priorly treated, glands that have had prior UroLifts or Rezums or prior TURPs or any of those procedures that have been done; [those] do not disqualify you from doing this procedure. I think that they would find this to be extremely useful in their practice.
This transcription has been edited for clarity.
